Dimerix Phase 3 Trial Last Patient Receives First Dose
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The trial is now closed to further recruitment of adult patients, although recruitment of paediatric patients continues as an independent cohort. The company is well positioned to advance the trial and explore licensing opportunities with potential partners.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Dimerix
- Appendix 4D and Half Year Financial Report
- Quarterly Appendix 4C and Activities Report
- BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
- DMX-200 ACTION3 Phase 3 trial completes recruitment
- Successful Completion of Planned IDMC Review
Later from Dimerix
- Dimerix to Conduct Review of ACTION3 Statistical Assumptions
- ACTION3 Statistical Review Complete
- Blinded assessment of ACTION3 statistical assumptions complete
- Dimerix Quarterly Activities Report and Appendix 4C
- Dimerix Licenses DMX200 to Everest for China and Asia Region
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix